Chronic Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chronic Pain Market Outlook
Thelansis’s “Chronic Pain Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Chronic Pain treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Chronic Pain Overview
Chronic
pain is a common, complex, and distressing problem that significantly impacts
society and individuals. It commonly arises as a consequence of injury or
disease. Many pain categories and types exist, encompassing neuropathic,
nociceptive, musculoskeletal, inflammatory, psychogenic, and mechanical pain.
Risk factors have been classified into “modifiable” and “non-modifiable.” The
primary clinical risk factor for chronic pain development is the coexistence of
acute or chronic pain at other bodily sites. The likelihood of chronic pain
increases in proportion to the severity and number of these sites. Painful
stimuli prompt alterations in brain chemistry that predispose individuals to
chronic pain. This heightened susceptibility can manifest within days of
continuous exposure to painful stimuli and persist for up to a year after pain
resolution. Both having multiple causes of chronic pain and enduring pain for
extended periods are associated with diminished quality of life. The
differential diagnosis for generalized chronic pain encompasses patients
experiencing allodynia due to chronic opioid use and those afflicted with major
depressive disorder, as well as individuals with other psychiatric or sleep
disorders like insomnia. Pharmacological therapies for chronic pain involve
nonopioid analgesics such as nonsteroidal anti-inflammatories (NSAIDs),
acetaminophen, and aspirin. Additionally, medications like tramadol, opioids,
antiepileptic drugs (e.g., gabapentin or pregabalin) are employed. Moreover,
antidepressants such as tricyclic antidepressants and selective
serotonin-norepinephrine reuptake inhibitors (SNRIs), topical analgesics,
muscle relaxants, N-methyl-D-aspartate (NMDA) receptor antagonists, and alpha-2
adrenergic agonists are utilized as pharmacological interventions.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment